DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Single Ventricle; Fontan Operation

Intervention: Treprostinil (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Stanford University

Official(s) and/or principal investigator(s):
Jeffrey Feinstein, Principal Investigator, Affiliation: Stanford University

Overall contact:
Jeffrey Feinstein, MD, MPH, Email: jeff.feinstein@stanford.edu


The purpose of this study is to test the efficacy of treprostinil in the perioperative non-fenestrated, extracardiac Fontan patients in order to reduce duration of chest tube drainage (in days). The Fontan operation is performed for patients with single ventricle physiology as the final palliation to create a series circulation, with passive systemic venous return to the pulmonary arteries and the single ventricle solely providing systemic output. Patients undergoing extracardiac Fontan tend to have elevation of Fontan pressures immediately following the operation with inflammation from surgery requiring additional fluid administration to maintain blood pressure. Increased Fontan pressures and fluid overload lead to prolonged chest tube drainage. The hypothesis is that treprostinil, a prostacyclin drug that dilates the pulmonary arteries, will improve immediate postoperative Fontan pressures. Treprostinil is not FDA approved for this use. Anecdotally and in a small case series, prostacyclin therapy has been shown to assist in transitioning patients off nitric oxide. The investigators believe that this improvement in hemodynamics will decrease duration of chest tube drainage resulting in a shorter length of hospital stay.

Clinical Details

Official title: Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Chest tube duration

Secondary outcome: Length of hospital stay

Detailed description: In order to understand the effect of treprostinil on Fontan patients, this study has two parts: 1. reactivity testing with inhaled treprostinil in the cardiac catheterization lab for pre-Fontan patients undergoing routine catheterization in anticipation of the Fontan operation; 2. perioperative use of subcutaneous treprostinil starting immediately pre-op until postoperative day #7 to improve immediate postoperative hemodynamics and ultimately reduce overall length of hospital stay. The investigators hope to learn how pulmonary vasodilator therapy affects and/or improves post- operative hemodynamics following the Fontan operation. This knowledge would be very important in the care of single ventricle patients following the Fontan operation if there is improvement of immediate outcomes and reduction of hospital length of stay. On a broader scale, if the use of treprostinil in perioperative Fontan patients can achieve the same results other centers achieve with the use of a fenestration this may have wide scale implications in the nationwide treatment of Fontan patients.


Minimum age: 1 Year. Maximum age: 18 Years. Gender(s): Both.


Inclusion Criteria:

- Pediatric patient undergoing Fontan operation and/or pre-Fontan cardiac

catheterization at Lucile Packard Children's Hospital (LPCH) Exclusion Criteria:

- Platelet count < 50K (treprostinil can act as a platelet inhibitor and this may place

patient at additional risk of bleeding if already thrombocytopenic)

- Dermatologic condition that renders the patient unable to tolerate a subcutaneous

infusion (can still take part in inhaled vasodilator testing during cardiac catheterization)

- Currently receiving any vasodilator therapy specifically for the purpose of pulmonary

vsasodilation (phosphodiesterase type 5 inhibitor, endothelia receptor antagonist and/or prostacyclin).

Locations and Contacts

Jeffrey Feinstein, MD, MPH, Email: jeff.feinstein@stanford.edu

Lucile Packard Children's Hospital, Stanford, Palo Alto, California 94304, United States; Not yet recruiting
Jeffrey Feinstein, MD, MPD, Principal Investigator
Stephanie Siehr, MD, Sub-Investigator
Additional Information

Starting date: September 2015
Last updated: July 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017